Navigation Links
Transgenomic, Inc. Announces Appointment of New Board Members

OMAHA, Neb., May 22 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) announces that it has appointed Antonius P. Schuh, Ph.D. and Michael B. McNulty to its Board of Directors.

Dr. Schuh is the Founding Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (STI). STI is a seed-stage biotechnology company built on a proprietary antibody library construction technology, the STI technology, which applies RNA transcription rather than PCR for the amplification of variable lgG domains to yield high fidelity mAb libraries. Prior to STI, Dr. Schuh was the Founding Chief Executive Officer and Director of AviaraDx, Inc. AviaraDx was a molecular diagnostics laboratory company focused on oncology testing which was acquired by bioMerieux. Before leading AviaraDx, Dr. Schuh was Chief Executive Officer of Arcturus Bioscience, Inc. and Sequenom, Inc.

Mr. McNulty is currently General Manager of Diagnostics at Agilent Technologies, Inc. Agilent Technologies Inc. is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. Prior to his current position he was Vice President of Laboratory Operations and Chief Compliance Officer of Berkeley Heartlabs, Inc. Mr. McNulty has previously served as a board member for Employee Health Programs, Bethesda, MD; Drug Free workplace, plc, London, UK; ThauMDx LLC, Santa Barbara, CA; and International Cancer Screening Laboratories, Inc. Mr. McNulty previously ran SmithKline Beecham's Chicago based reference laboratory prior to the company's transition to become Quest Diagnostics.

In making this announcement, Transgenomic President and CEO, Craig Tuttle, stated, "We are very excited to have Dr. Schuh and Mr. McNulty join the Company's Board of Directors. Combined, they have considerable experience in molecular diagnostics and, equally important, success in leading and running diagnostic reference laboratories. With our continued focus on growing Transgenomic's molecular diagnostic laboratory and pharmacogenomic services lab, plus focusing our WAVE system and related mutation detection technology for greater diagnostic and clinical value, their participation on our board will provide a vital increase in laboratory experience and guidance."

About Transgenomic

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of Pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, Cytogenetics automated systems, and Transgenomic Pharmacogenomics and Reference Laboratory Services. Transgenomic Pharmacogenomics and Laboratory Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit:

Cautionary Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release.

SOURCE Transgenomic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Transgenomic, Inc. Forms Scientific Advisory Board
3. Transgenomic, Inc. Reports Third Quarter 2008 Results
4. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
5. Transgenomic, Inc. Reports First Quarter 2009 Results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... ... 24, 2015 , ... International Society for Pharmaceutical Engineering (ISPE) ... annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in ... largest number of attendees in more than a decade. , “The 2015 ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
Breaking Biology Technology:
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
Breaking Biology News(10 mins):